XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Stock Option Plan (Tables)
3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
Stock option activity under the Company's 2019 Plan is set forth below:
 
Number of
Options
Weighted-
Average
Exercise Price
Weighted-
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value (in thousands)
Outstanding, December 31, 20212,014,330 $12.10 7.87$5,428 
Forfeited(8,396)$14.08 
Expired(3,895)$14.30 
Outstanding, March 31, 2022
2,002,039 $12.08 7.63$3,661 
Vested and expected to vest, March 31, 2022
2,002,039 $12.08 7.63$3,661 
Options exercisable, March 31, 2022
1,188,164 $10.47 7.35$3,124 
Schedule of Restricted Stock Unit Activity
Restricted stock unit activity under the Company's 2019 Plan is set forth below:
Number of
Shares
Weighted-
Average
Grant Date Fair Value
Aggregate
Intrinsic
Value (in thousands)
Outstanding, December 31, 2021415,325 $16.54 $4,830 
Awards granted529,100 $8.72 
Awards released(46,625)$18.19 
Awards canceled(19,225)$13.75 
Outstanding, March 31, 2022
878,575 $11.81 $7,055 
Schedule of Fair Value Assumptions, Stock Options
The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:
 
 Three Months Ended March 31,
 2021
Expected volatility
84%
Risk-free interest rate
0.8%
Dividend yield
Expected term (in years)
6.08
Schedule of Fair Value Assumptions, Employee Stock Purchase Plan
The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:
 Three Months Ended March 31,
 20222021
Expected volatility45%60%
Risk-free interest rate0.6%0.1%
Dividend yield
Expected term (in years)0.500.50
Schedule of Non-cash Stock-based Compensation Expense Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statements of operations is as follows (in thousands): 
 Three Months Ended March 31,
 20222021
Costs of revenue$44 $11 
Selling, general and administrative1,118 791 
Research and development214 110 
Total$1,376 $912